Rituximab for the treatment of relapsed/refractory chronic lymphocytic leukaemia.

Health technology assessment (Winchester, England)

Volumn 14, Issue Suppl. 2, 2010, Pages 19-26

  Dretzke, J ^a   Barton, P ^b   Kaambwa, B ^b   Connock, M ^b   Uthman, O ^b   Bayliss, S ^b   Meads, C ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; RITUXIMAB;

CHRONIC LYMPHATIC LEUKEMIA; COST BENEFIT ANALYSIS; ECONOMICS; HUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; UNITED KINGDOM;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; COST-BENEFIT ANALYSIS; ENGLAND; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; WALES;

EID: 84886943221     PISSN: None     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta14suppl2/03     Document Type: Review

References (0)